GRAIL's 24% Galleri Growth Is Real-But Is That Enough to Justify the Bet Before the FDA Panel?

Galleri growth is clear, but losses still frame the valuation debate

Bulls can point to real adoption, not just a future-tense story. In Q2, Galleri revenue grew 24% to $42.6 million, total revenue reached $44.7 million, and test volume rose to more than 61,000. For the first half of the year, Galleri revenue increased 30% and volume increased 42%.

Revenue is scaling; profitability still looks distant

The same quarter kept the valuation call tense. GRAIL reported a net loss of $110.2 million and a gross loss of $12.6 million, even as it said cash, cash equivalents, and short-term marketable securities totaled $861.6 million at June 30. That gives the company runway, but it does not remove the pressure around valuation.

Why the FDA panel is the next real hinge

The near-term catalyst is the FDA panel scheduled for Sept. 23, 2026, which will review Galleri's PMA application. Bulls see current adoption as a reason approval could trigger a rerating. Bears see pre-approval uptake as incomplete proof until reimbursement and standard-of-care integration become clearer.

The debate is less about demand than about approval, payment, and durability

Early commercial activity already suggests doctors and screened populations are using Galleri. The harder question is whether regulators, payers, and larger health systems will treat that activity as the start of a reimbursable screening pathway-or merely as early demand for a test that still needs more long-run evidence.

What the FDA review is built on

The PMA submission relies on 25,490 consented participants in PATHFINDER 2 and the prevalent round of the NHS-Galleri trial. Across both studies, GRAIL says the program includes more than 174,000 participants enrolled across both studies. That scale matters because screening tests usually face a higher bar than many diagnostics.

The immediate gate is the panel on Sept. 23, 2026. A constructive outcome could make today's demand look more durable and easier to pay for. A tougher hearing could push reimbursement discussions and broader adoption further into the future.

Clinical evidence helps, but payers are the next test

GRAIL has built its case on stronger study design than many new screening candidates: the only randomized controlled trial of an MCED test in NHS-Galleri, plus PATHFINDER 2 as the largest MCED interventional study in North America in an intended-use, asymptomatic population.

Still, even if approval odds improve, payers will likely want evidence that earlier detection changes outcomes enough to justify payment at scale. That means a positive regulatory signal alone may not be enough to unlock the valuation case on its own.

What matters most from here: - Whether ASCO adds confidence to the full PATHFINDER 2 dataset - Whether test performance and safety results hold up under regulatory scrutiny - Whether the Sept. 23 meeting looks more supportive than skeptical

What to watch after the panel-and what would change the valuation call

With adoption already visible and losses still in the story, the next signal that matters most is the regulatory read-through. Once again, the central question is whether backing from FDA advisers makes Galleri's current demand look durable, reimbursable, and scalable.

Panel triggers worth watching

Watch for these signals: - Whether the panel's tone on the PMA application looks supportive or skeptical - Whether randomized controlled study evidence helps close the panel's hardest questions rather than reopening them - Whether management can connect clinical utility to a plausible payment pathway, not just to scientific credibility

Post-panel proof points

Approval chatter is only part of the story. Investors also need evidence that demand can become a payable business.

Check these developments after the meeting: - Payer messaging: Are coverage and reimbursement conversations progressing, or do they remain in research-use territory? - Commercial conversion: Does current demand look like it can shift from voluntary adoption into repeat, scaled utilization? - Margin visibility: Is the business moving toward a clearer path from test orders to monetization?

What would weaken the bullish case

The current valuation thesis would look less secure if: - The panel debate centers on significant evidence gaps in PATHFINDER 2 or NHS-Galleri - No clear payer pathway emerges after the meeting - Growth continues without a visible path to operating leverage, with losses still dominating the story

For now, fair value still looks conditional rather than confirmed, pending stronger signals on both regulatory support and payment.